$15.29
0[0.00%]
At close: Apr 24
$15.29
0[0.00%]
PreMarket: 4:00PM EDT
Y-mAbs Therapeutics
(NASDAQ:YMAB)Latest News for Y-mAbs Therapeutics Stock (NASDAQ:YMAB)
Y-mAbs Therapeutics Stock (NASDAQ: YMAB)
Categories: All
Thursday, March 14, 2024
Wednesday, March 06, 2024
Monday, March 04, 2024
Friday, March 01, 2024
- Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day SessionAvi Kapoor - Mar 1, 2024, 1:19PM
- Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On FridayAvi Kapoor - Mar 1, 2024, 11:18AM
- Why NetApp Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 1, 2024, 8:31AM
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga Insights - Mar 1, 2024, 8:09AM
Thursday, February 29, 2024
- Y-mAbs Therapeutics Q4 2023 GAAP EPS $(0.020) Beats $(0.210) Estimate, Sales $23.363M Beat $20.955M EstimateBenzinga Newsdesk - Feb 29, 2024, 4:56PM
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga Insights - Feb 29, 2024, 4:31PM
- Earnings Scheduled For February 29, 2024Benzinga Insights - Feb 29, 2024, 5:15AM
Wednesday, February 28, 2024
Tuesday, February 20, 2024
Monday, January 15, 2024
Friday, January 12, 2024
Thursday, November 30, 2023
Wednesday, November 15, 2023
Monday, November 13, 2023
- Y-mAbs Therapeutics Q3 EPS $(0.18) Beats $(0.19) Estimate, Sales $19.95M Miss $20.93M EstimateBenzinga Newsdesk - Nov 13, 2023, 5:34PM
- Y-mAbs Q3 DANYELZA Net Product Revenues $20M, Up 59% YoYBenzinga Newsdesk - Nov 13, 2023, 4:06PM
- Earnings Scheduled For November 13, 2023Benzinga Insights - Nov 13, 2023, 6:40AM
Friday, November 10, 2023
Thursday, November 09, 2023
Wednesday, October 18, 2023
Tuesday, October 17, 2023
Monday, October 16, 2023
Tuesday, August 22, 2023
Monday, August 14, 2023
- 4 Analysts Have This to Say About Y-mAbs TherapeuticsBenzinga Insights - Aug 14, 2023, 9:00AM
- Morgan Stanley Maintains Underweight on Y-mAbs Therapeutics, Lowers Price Target to $5Benzinga Newsdesk - Aug 14, 2023, 8:31AM
- HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $11 Price TargetBenzinga Newsdesk - Aug 14, 2023, 6:44AM
Thursday, August 10, 2023
- Y-mAbs Therapeutics Reiterates FY23 Revenue $80M-$85M Vs $82.79M EstBenzinga Newsdesk - Aug 10, 2023, 4:28PM
- Y-mAbs Therapeutics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $20.80M Beat $20.35M EstimateBenzinga Newsdesk - Aug 10, 2023, 4:08PM
- Earnings Scheduled For August 10, 2023Benzinga Insights - Aug 10, 2023, 6:59AM
Tuesday, July 25, 2023
Wednesday, June 07, 2023
Tuesday, May 23, 2023
Monday, May 15, 2023
- B of A Securities Maintains Neutral Rating for Y-mAbs Therapeutics: Here's What You Need To KnowBenzinga Insights - May 15, 2023, 1:00PM
- Sarepta Therapeutics, C3.ai, monday.com, And Other Big Stocks Moving Higher On MondayLisa Levin - May 15, 2023, 10:27AM
- Y-mAbs Therapeutics shares are trading higher after B of A Securities maintained a Neutral rating on the stock and raised its price target from $6 to $12.Benzinga Newsdesk - May 15, 2023, 10:16AM
- B of A Securities Maintains Neutral on Y-mAbs Therapeutics, Raises Price Target to $12Benzinga Newsdesk - May 15, 2023, 9:08AM
Wednesday, May 10, 2023
- Analyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved VisibilityVandana Singh - May 10, 2023, 3:10PM
- Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023Benzinga Insights - May 10, 2023, 11:00AM
- Morgan Stanley Maintains Underweight on Y-mAbs Therapeutics, Raises Price Target to $7Benzinga Newsdesk - May 10, 2023, 8:18AM
- Wedbush Upgrades Y-mAbs Therapeutics to Outperform, Raises Price Target to $13Benzinga Newsdesk - May 10, 2023, 6:56AM